D-dimer
D-dimer is a fibrin degradation product formed when cross-linked fibrin is broken down by plasmin during fibrinolysis.
D-dimer is a fibrin degradation product formed when cross-linked fibrin is broken down by plasmin during fibrinolysis. Clinically, it is used as a biomarker of coagulation activation and clot turnover, reflecting the presence of recent or ongoing thrombosis, disseminated intravascular coagulation, severe inflammation, and other states associated with increased fibrin formation and breakdown. Because it is generated only after factor XIII-mediated fibrin cross-linking and subsequent fibrinolysis, D-dimer is more specific for intravascular clot formation than fibrinogen alone, although it is not specific for any single disease.
In routine medicine, D-dimer is most often used in the evaluation of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, and it is also studied in systemic lupus erythematosus, COVID-19, trauma, infection, malignancy, and other prothrombotic or inflammatory conditions. In these settings, D-dimer is typically interpreted alongside other coagulation and inflammation markers such as fibrinogen, thrombomodulin, thrombin-antithrombin complex, tissue plasminogen activator-inhibitor complex, C-reactive protein, ferritin, and prothrombin parameters. Elevated levels may indicate thrombotic risk, disease severity, or poor prognosis, but clinical interpretation depends strongly on the underlying context.
Where the papers sit
12 papers from the last 6 months study d-dimer directly · updated from PubMed 15 Nov 2026
Study type 1 clinical trial · 5 observational · 6 human data
Themes 3 themes · 1 paradigm shift
-
Coagulation Biomarkers in Acute Care
Coagulation markers are being used to estimate bleeding, thrombosis and mortality risk across acute-care settings. D-dimer, fibrin degradation products and fibrinogen recur in studies of traumatic brain injury, severe trauma, heart failure and geriatric hip fracture. Composite inflammation-nutrition-coagulation scores extend prediction to one-year mortality, while serial testing targets venous thromboembolism. Multiplex immunosensors are moving measurement toward rapid simultaneous testing, but clinical utility remains unsettled.
6 papers · 50%
-
COVID-19 Severity Biomarkers
COVID-19 severity assessment is moving toward blood-based risk stratification for respiratory support and prognosis. The lactate dehydrogenase-to-albumin ratio is linked to oxygen therapy requirements and dyspnea-related measures. Plasma proteomics highlights SERPINA1 and CD59 as candidate markers for severity and survival prediction. Receiver operating characteristic analysis supports clinical discrimination, but external validation remains needed.
2 papers · 16.7%
-
Others — Coagulation Risk Across Diseases
D-dimer and related coagulation measures are being applied to infection risk, thrombosis prevention, graft viability and cancer prognosis. Rivaroxaban is compared with aspirin for pulmonary embolism and deep-vein thrombosis prevention, while flavin mononucleotide and D-dimer support liver graft assessment during machine perfusion. D-dimer, von Willebrand factor and factor VIII are also evaluated in acute myeloid leukemia, alongside machine-learning prediction of infection in systemic lupus erythematosus. These applications share clinical risk assessment but show no single emerging direction.
4 papers · 33.3%
D-dimer is not a dependable standalone marker for disease severity or biological outcome
The COVID-19 plasma-proteomics study and the hypothermic oxygenated machine-perfusion liver-transplantation study both weaken the assumption that D-dimer alone reliably identifies clinically important outcomes: in COVID-19, D-dimer and fibrin degradation products were described as having limited accuracy for severity and long-term prognosis, while in liver graft perfusion, flavin mononucleotide—not D-dimer—showed the association with post-transplant cholangiopathy and graft loss. The implication is that D-dimer should not be treated as a sufficient standalone discriminator when more informative biomarker combinations or alternative markers are available (PMIDs 42323884, 42817598).
Papers
The 12 papers from the last 6 months that study d-dimer directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Coagulation Biomarkers in Acute Care (6)
- A composite inflammation-nutrition-coagulation score and 1-year mortality in geriatric proximal femur fractures: a retrospective cohort study. Archives of orthopaedic and trauma surgery · 31 Oct 2026 PMID 42963489
- Association of D-dimer, fibrin degradation products, and coagulation parameters with progressive hemorrhagic injury following traumatic brain injury: A retrospective cohort study. Medicine · 9 Oct 2026 PMID 42854043
- The relationship between D-dimer and the risk for adverse outcomes in patients with heart failure. Laboratory medicine · 5 Oct 2026 PMID 42832500
- An Integrated Cartridge-Based Multiplex Chemiluminescent Immunosensor Platform for the Simultaneous Quantification of Five Coagulation and Fibrinolysis Biomarkers. Analytical chemistry · 11 Aug 2026 PMID 42578868
- Multiplexed Sepsis Immunosorbent Assay Based on Flower-like CoFe2O4/MoS2 with Dual Substrate Affinity. Analytical chemistry · 26 Jun 2026 PMID 42360892
- The Trajectories of Platelet, Fibrinogen, and D-dimer in Severe Trauma Patients and Their Value in Predicting Venous Thromboembolism: A Retrospective Study. Dimensions of critical care nursing : DCCN · 28 May 2026 PMID 42207594
COVID-19 Severity Biomarkers (2)
- Association between lactate dehydrogenase-to-albumin ratio and oxygen therapy requirement in hospitalized patients with COVID-19: A retrospective observational study. Medicine · 18 Jul 2026 PMID 42470040
- Plasma proteomics reveal SERPINA1 and CD59 as candidate biomarkers for COVID-19 severity stratification and prognosis prediction. Annals of medicine · 21 Jun 2026 PMID 42323884
Others — Coagulation Risk Across Diseases (4)
- Perfusate Flavin Mononucleotide and D-Dimer as Viability Biomarkers in Australasia's First Hypothermic Machine Perfusion Programme for Liver Transplantation. Clinical transplantation · 1 Oct 2026 PMID 42817598
- An explainable machine learning model for predicting in-hospital infection in patients with systemic lupus erythematosus. Renal failure · 5 Aug 2026 PMID 42557059
- Von Willebrand, factor VIII, and D-dimer levels as predictors of risk and clinical outcomes in acute myeloid leukemia. Clinical and experimental medicine · 20 Jul 2026 PMID 42474591
- Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial. Lupus science & medicine · 20 May 2026 PMID 42161432
By study type
Clinical trials (1)
- Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial. Lupus science & medicine · 20 May 2026 PMID 42161432
Observational studies and case reports (5)
- A composite inflammation-nutrition-coagulation score and 1-year mortality in geriatric proximal femur fractures: a retrospective cohort study. Archives of orthopaedic and trauma surgery · 31 Oct 2026 PMID 42963489
- Association of D-dimer, fibrin degradation products, and coagulation parameters with progressive hemorrhagic injury following traumatic brain injury: A retrospective cohort study. Medicine · 9 Oct 2026 PMID 42854043
- Perfusate Flavin Mononucleotide and D-Dimer as Viability Biomarkers in Australasia's First Hypothermic Machine Perfusion Programme for Liver Transplantation. Clinical transplantation · 1 Oct 2026 PMID 42817598
- Association between lactate dehydrogenase-to-albumin ratio and oxygen therapy requirement in hospitalized patients with COVID-19: A retrospective observational study. Medicine · 18 Jul 2026 PMID 42470040
- The Trajectories of Platelet, Fibrinogen, and D-dimer in Severe Trauma Patients and Their Value in Predicting Venous Thromboembolism: A Retrospective Study. Dimensions of critical care nursing : DCCN · 28 May 2026 PMID 42207594
Human data, design not indexed (6)
- The relationship between D-dimer and the risk for adverse outcomes in patients with heart failure. Laboratory medicine · 5 Oct 2026 PMID 42832500
- An Integrated Cartridge-Based Multiplex Chemiluminescent Immunosensor Platform for the Simultaneous Quantification of Five Coagulation and Fibrinolysis Biomarkers. Analytical chemistry · 11 Aug 2026 PMID 42578868
- An explainable machine learning model for predicting in-hospital infection in patients with systemic lupus erythematosus. Renal failure · 5 Aug 2026 PMID 42557059
- Von Willebrand, factor VIII, and D-dimer levels as predictors of risk and clinical outcomes in acute myeloid leukemia. Clinical and experimental medicine · 20 Jul 2026 PMID 42474591
- Multiplexed Sepsis Immunosorbent Assay Based on Flower-like CoFe2O4/MoS2 with Dual Substrate Affinity. Analytical chemistry · 26 Jun 2026 PMID 42360892
- Plasma proteomics reveal SERPINA1 and CD59 as candidate biomarkers for COVID-19 severity stratification and prognosis prediction. Annals of medicine · 21 Jun 2026 PMID 42323884
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-08-13. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.